enVVeno Medical Corp Ordinary Shares NVNO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
enVVeno Medical Releases New Episode of "WTF" Video Series Featuring CEO Rob Berman
-
enVVeno Medical's First-in-Class enVVe System to Be Featured at The VEINS 2026 Innovation Summit as Company Advances Toward U.S. Pivotal Trial
-
enVVeno Medical CEO Rob Berman Goes Direct to Investors with New "WTF" Video Series
-
enVVeno Medical Presentation from H.C. Wainwright Conference Now Available On-Demand
-
enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference
-
Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatments
-
enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve
-
EnVVeno Medical Loses Appeal of FDA Not-Approvable Letter for VenoValve
Trading Information
- Previous Close Price
- $6.75
- Day Range
- $6.93–7.25
- 52-Week Range
- $6.62–26.14
- Bid/Ask
- $6.96 / $7.31
- Shares Outstanding
- 694,826.00
- Market Cap
- $4.87M
- Volume/Avg
- 11,736 / 27,291
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
enVVeno Medical Corp is a medical device company focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The company first developed the VenoValve, which was a surgical replacement venous valve. It is focused on its next-generation, non-surgical venous valve product, called the enVVe System which consists of the enVVe Valve, enVVe Delivery System, enVVe Nose Cone, the enVVe Delivery System Accessories, and the enVVe Crimping System. The enVVe System is designed to treat severe deep chronic venous insufficiency through a minimally invasive, catheter-based approach. It operates in a single segment, Medical Device development, located in a single geographic location, the United States.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 33
- Website
- https://www.envveno.com
Valuation
|
Metric
|
NVNO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.22 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
NVNO
|
|---|---|
Quick Ratio | 11.39 |
Current Ratio | 11.70 |
Interest Coverage | — |
Quick Ratio
NVNO
Profitability
|
Metric
|
NVNO
|
|---|---|
Return on Assets (Normalized) | −48.41% |
Return on Equity (Normalized) | −53.17% |
Return on Invested Capital (Normalized) | −52.95% |
Return on Assets
NVNO
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|%^?@<#N | LOCK|zlv>K | $178B | |||
| Medtronic PLC
MDT
| LOCK|&!?vh@ | LOCK|DgNLb | $121B | |||
| Stryker Corp
SYK
| LOCK|sxKXtTDR | LOCK|CK | $117B | |||
| Boston Scientific Corp
BSX
| LOCK|G&%J!!@ | LOCK|Dq!Vt | $61B | |||
| Edwards Lifesciences Corp
EW
| LOCK|&Rx^^<Kv | LOCK|&#Ks | $53B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| LOCK|%RH@l%z | LOCK|Ht | $34B | |||
| DexCom Inc
DXCM
| LOCK|^jkr$Zr | LOCK|c%R@j | $30B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|<^? | LOCK|?#$ | $26B | |||
| Steris PLC
STE
| LOCK|%PTpKJ# | LOCK|z!Bx& | $22B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|hM@#CQGc | LOCK|<B | $18B |
United States